

# Basic Drug List Updates

January 2020

<b>TRADE NAME (generic name) or generic name</b>	<b>Brand/Generic Product</b>	<b>Description of Change</b>
BELBUCA (buprenorphine hcl buccal film 150 mcg (base equivalent))	Brand	Addition, Preferred Status
BELBUCA (buprenorphine hcl buccal film 300 mcg (base equivalent))	Brand	Addition, Preferred Status
BELBUCA (buprenorphine hcl buccal film 450 mcg (base equivalent))	Brand	Addition, Preferred Status
BELBUCA (buprenorphine hcl buccal film 600 mcg (base equivalent))	Brand	Addition, Preferred Status
BELBUCA (buprenorphine hcl buccal film 75 mcg (base equivalent))	Brand	Addition, Preferred Status
BELBUCA (buprenorphine hcl buccal film 750 mcg (base equivalent))	Brand	Addition, Preferred Status
BELBUCA (buprenorphine hcl buccal film 900 mcg (base equivalent))	Brand	Addition, Preferred Status
EMGALITY (galcanezumab-gnlm subcutaneous soln prefilled syr 100 mg/ml)	Brand	Addition, Preferred Status
EXJADE (deferasirox tab for oral susp 125 mg)	Brand	Removal, Non-Preferred Status, generics available
EXJADE (deferasirox tab for oral susp 250 mg)	Brand	Removal, Non-Preferred Status, generics available
EXJADE (deferasirox tab for oral susp 500 mg)	Brand	Removal, Non-Preferred Status, generics available
FIASP PENFILL (insulin aspart (with niacinamide) soln cartridge 100 unit/ml)	Brand	Addition, Preferred Status
LETAIRIS (ambrisentan tab 10 mg)	Brand	Removal, Non-Preferred Status, generics available
LETAIRIS (ambrisentan tab 5 mg)	Brand	Removal, Non-Preferred Status, generics available
LINZESS (linaclotide cap 145 mcg)	Brand	Removal, Non-Preferred Status
LINZESS (linaclotide cap 290 mcg)	Brand	Removal, Non-Preferred Status
LINZESS (linaclotide cap 72 mcg)	Brand	Removal, Non-Preferred Status
MAVENCLAD (cladribine tab therapy pack 10 mg (10 tabs))	Brand	Addition, Preferred Status
MAVENCLAD (cladribine tab therapy pack 10 mg (4 tabs))	Brand	Addition, Preferred Status
MAVENCLAD (cladribine tab therapy pack 10 mg (5 tabs))	Brand	Addition, Preferred Status
MAVENCLAD (cladribine tab therapy pack 10 mg (6 tabs))	Brand	Addition, Preferred Status
MAVENCLAD (cladribine tab therapy pack 10 mg (7 tabs))	Brand	Addition, Preferred Status
MAVENCLAD (cladribine tab therapy pack 10 mg (8 tabs))	Brand	Addition, Preferred Status
MAVENCLAD (cladribine tab therapy pack 10 mg (9 tabs))	Brand	Addition, Preferred Status
NORDITROPIN FLEXPRO (somatropin inj 10 mg/1.5ml)	Brand	Addition, Preferred Status
NORDITROPIN FLEXPRO (somatropin inj 15 mg/1.5ml)	Brand	Addition, Preferred Status
NORDITROPIN FLEXPRO (somatropin inj 30 mg/3ml)	Brand	Addition, Preferred Status
NORDITROPIN FLEXPRO (somatropin inj 5 mg/1.5ml)	Brand	Addition, Preferred Status
OMNITROPE (somatropin for inj 5.8 mg)	Brand	Removal, Non-Preferred Status
OMNITROPE (somatropin inj 10 mg/1.5ml)	Brand	Removal, Non-Preferred Status
OMNITROPE (somatropin inj 5 mg/1.5ml)	Brand	Removal, Non-Preferred Status
PIQRAY 200MG DAILY DOSE (alpelisib tab therapy pack 200 mg daily dose)	Brand	Addition, Preferred Status
PIQRAY 250MG DAILY DOSE (alpelisib tab pack 250 mg daily dose (200 mg & 50 mg tabs))	Brand	Addition, Preferred Status
PIQRAY 300MG DAILY DOSE (alpelisib tab pack 300 mg daily dose (2x150 mg tab))	Brand	Addition, Preferred Status
PROGLYCEM (diazoxide susp 50 mg/ml)	Brand	Addition, Preferred Status
RINVOQ (upadacitinib tab er 24hr 15 mg)	Brand	Addition, Preferred Status
SENSIPAR (cinacalcet hcl tab 30 mg (base equiv))	Brand	Removal, Non-Preferred Status, generics available

<b>TRADE NAME (generic name) or generic name</b>	<b>Brand/Generic Product</b>	<b>Description of Change</b>
SENSIPAR (cinacalcet hcl tab 60 mg (base equiv))	Brand	Removal, Non-Preferred Status, generics available
SENSIPAR (cinacalcet hcl tab 90 mg (base equiv))	Brand	Removal, Non-Preferred Status, generics available
SIMPONI (golimumab subcutaneous soln auto-injector 100 mg/ml)	Brand	Removal, Non-Preferred Status
SIMPONI (golimumab subcutaneous soln auto-injector 50 mg/0.5ml)	Brand	Removal, Non-Preferred Status
SIMPONI (golimumab subcutaneous soln prefilled syringe 100 mg/ml)	Brand	Removal, Non-Preferred Status
SIMPONI (golimumab subcutaneous soln prefilled syringe 50 mg/0.5ml)	Brand	Removal, Non-Preferred Status
SUBOXONE (buprenorphine hcl-naloxone hcl sl film 12-3 mg (base equiv))	Brand	Removal, Non-Preferred Status, generics available
SUBOXONE (buprenorphine hcl-naloxone hcl sl film 2-0.5 mg (base equiv))	Brand	Removal, Non-Preferred Status, generics available
SUBOXONE (buprenorphine hcl-naloxone hcl sl film 4-1 mg (base equiv))	Brand	Removal, Non-Preferred Status, generics available
SUBOXONE (buprenorphine hcl-naloxone hcl sl film 8-2 mg (base equiv))	Brand	Removal, Non-Preferred Status, generics available
SUNOSI (solriamfetol hcl tab 150 mg (base equiv))	Brand	Addition, Preferred Status
SUNOSI (solriamfetol hcl tab 75 mg (base equiv))	Brand	Addition, Preferred Status
SYMPROIC (naldemedine tosylate tab 0.2 mg (base equivalent))	Brand	Addition, Preferred Status
TARCEVA (erlotinib hcl tab 100 mg (base equivalent))	Brand	Removal, Non-Preferred Status, generics available
TARCEVA (erlotinib hcl tab 150 mg (base equivalent))	Brand	Removal, Non-Preferred Status, generics available
TARCEVA (erlotinib hcl tab 25 mg (base equivalent))	Brand	Removal, Non-Preferred Status, generics available
TRULANCE (plecanatide tab 3 mg)	Brand	Addition, Preferred Status
VERZENIO (abemaciclib tab 100 mg)	Brand	Addition, Preferred Status
VERZENIO (abemaciclib tab 150 mg)	Brand	Addition, Preferred Status
VERZENIO (abemaciclib tab 200 mg)	Brand	Addition, Preferred Status
VERZENIO (abemaciclib tab 50 mg)	Brand	Addition, Preferred Status
VESICARE (solifenacin succinate tab 10 mg)	Brand	Removal, Non-Preferred Status, generics available
VESICARE (solifenacin succinate tab 5 mg)	Brand	Removal, Non-Preferred Status, generics available
VITRAKVI (larotrectinib sulfate cap 100 mg (base equivalent))	Brand	Addition, Preferred Status
VITRAKVI (larotrectinib sulfate cap 25 mg (base equivalent))	Brand	Addition, Preferred Status
VITRAKVI (larotrectinib sulfate oral soln 20 mg/ml (base equivalent))	Brand	Addition, Preferred Status
VYNDAMAX (tafamidis cap 61 mg)	Brand	Addition, Preferred Status
VYNDAQEL (tafamidis meglumine (cardiac) cap 20 mg)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.